These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 26950376)

  • 41. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma.
    Porrata LF; Gertz MA; Inwards DJ; Litzow MR; Lacy MQ; Tefferi A; Gastineau DA; Dispenzieri A; Ansell SM; Micallef IN; Geyer SM; Markovic SN
    Blood; 2001 Aug; 98(3):579-85. PubMed ID: 11468153
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors.
    Reich G; Mapara MY; Reichardt P; Dörken B; Maschmeyer G
    Bone Marrow Transplant; 2001 Mar; 27(5):525-9. PubMed ID: 11313687
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Mobilization of peripheral blood stem cells with plerixafor in poor mobilizer patients].
    Sancho JM; Duarte R; Medina L; Querol S; Marín P; Sureda A;
    Med Clin (Barc); 2016 Sep; 147(5):223.e1-223.e7. PubMed ID: 27374031
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treosulfan conditioning for allogeneic transplantation in multiple myeloma - improved overall survival in first line haematopoietic stem cell transplantation - a large retrospective study by the Chronic Malignancies Working Party of the EBMT.
    Gran C; Wang J; Nahi H; Koster L; Gahrton G; Einsele H; Niittyvoupio R; Edinger M; Beelen D; Ciceri F; Bornhäuser M; Finke J; de Wreede LC; Ljungman P; Mielke S; Tischer J; Garderet L; Schönland S; Yakoub-Agha I; Kröger N
    Br J Haematol; 2020 Jun; 189(5):e213-e217. PubMed ID: 32301111
    [No Abstract]   [Full Text] [Related]  

  • 45. Autologous peripheral blood progenitor cells cryopreserved with 5 and 10 percent dimethyl sulfoxide alone give comparable hematopoietic reconstitution after transplantation.
    Akkök CA; Liseth K; Nesthus I; Løkeland T; Tefre K; Bruserud O; Abrahamsen JF
    Transfusion; 2008 May; 48(5):877-83. PubMed ID: 18298599
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
    Özkurt ZN; Sucak GT; Akı ŞZ; Yağcı M; Haznedar R
    Cancer Invest; 2017 Mar; 35(3):195-201. PubMed ID: 28112977
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk of febrile neutropenia among patients with multiple myeloma or lymphoma who undergo inpatient versus outpatient autologous stem cell transplantation: a systematic review and meta-analysis.
    Owattanapanich W; Suphadirekkul K; Kunacheewa C; Ungprasert P; Prayongratana K
    BMC Cancer; 2018 Nov; 18(1):1126. PubMed ID: 30445930
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Plerixafor use in patients with previous mobilization failure: A multicenter experience.
    Tekgündüz E; Altuntaş F; Sıvgın S; Akı SZ; Dönmez A; Topçuoğlu P; Yıldırım R; Baysal NA; Ayyıldız E; Yüksel MK; Sarı I; Tombuloğlu M; Unal A; Ilhan O
    Transfus Apher Sci; 2012 Aug; 47(1):77-80. PubMed ID: 22609192
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A retrospective study of autologous stem cell mobilization to guide an immediate salvage protocol using plerixafor for patients who mobilize stem cells poorly.
    Hay AE; Lawrie A; Robinson N; Dong B; Culligan DJ
    J Clin Apher; 2013 Oct; 28(5):378-80. PubMed ID: 23483573
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Morbidity and Mortality in Autologous Stem Cell Transplantation.
    Berro M; Arbelbide JA; Rivas MM; Basquiera AL; Ferini G; Vitriu A; Foncuberta C; Fernandez Escobar N; Requejo A; Milovic V; Yantorno S; Szelagoswki M; Martinez Rolon J; Bentolila G; Garcia JJ; Garcia P; Caeiro G; Castro M; Jaimovich G; Palmer S; Trucco JI; Bet LA; Shaw BE; Kusminsky GD
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1646-1650. PubMed ID: 28669923
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Unsuccessful stem cell remobilization for autologous transplantation is predicted by renal impairment and a stem cell yield ≤ 0.5 X 10(6) CD34+ cells/kg at first mobilization.
    Hill QA; Pearce R; Cook G
    Bone Marrow Transplant; 2012 Oct; 47(10):1372-3. PubMed ID: 22343671
    [No Abstract]   [Full Text] [Related]  

  • 52. Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience.
    Lee KH; Jung SK; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW; Kim DW; Kang ES
    Vox Sang; 2014 Nov; 107(4):407-15. PubMed ID: 25130876
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
    Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
    [No Abstract]   [Full Text] [Related]  

  • 54. Granulocyte-colony stimulating factor response is superior to neutropenia duration in predicting the risk of infection after high-dose chemotherapy for myeloma and lymphoma.
    Straka C; Salwender H; Schnabel B; Sandherr M; Wandt H; Hübel K; Scheid C; Metzner B; Hentrich M; Franke D; Weidenegger G; Freund M; Sezer O; Einsele H; Hinke A; Emmerich B
    Leuk Lymphoma; 2015 Feb; 56(2):368-76. PubMed ID: 24794810
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma.
    Graff TM; Singavi AK; Schmidt W; Eastwood D; Drobyski WR; Horowitz M; Palmer J; Pasquini M; Rizzo DJ; Saber W; Hari P; Fenske TS
    Bone Marrow Transplant; 2015 Jul; 50(7):947-53. PubMed ID: 25867651
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Edentulism and transplant-associated complications in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation.
    Toro JJ; Gushiken FC; Schneider D; Lee S; Haile DJ; Freytes CO
    Support Care Cancer; 2016 Aug; 24(8):3411-5. PubMed ID: 26984247
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma.
    Batlle M; Morgades M; Vives S; Ferrà C; Oriol A; Sancho JM; Xicoy B; Moreno M; Magallón L; Ribera JM
    Eur J Haematol; 2014 Dec; 93(6):487-91. PubMed ID: 24889275
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Incidence of infection according to intravenous immunoglobulin use in autologous hematopoietic stem cell transplant recipients with multiple myeloma.
    Park S; Jung CW; Jang JH; Kim SJ; Kim WS; Kim K
    Transpl Infect Dis; 2015 Oct; 17(5):679-87. PubMed ID: 26201517
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
    Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
    J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Incidence and risk factors for acute kidney injury following autologous stem cell transplantation for multiple myeloma.
    Andronesi AG; Tanase AD; Sorohan BM; Craciun OG; Stefan L; Varady Z; Lipan L; Obrisca B; Truica A; Ismail G
    Cancer Med; 2019 Jun; 8(6):3278-3285. PubMed ID: 31016881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.